((lp0
VisWord
p1
aVcase
p2
aVstops
p3
aVstem
p4
acnltk.probability
FreqDist
p5
((dp6
S'acute coronary syndrom'
p7
I16
sS'inpatient initiation of'
p8
I1
sS'coronary diseas'
p9
I8
sS'statins for'
p10
I1
sS'abbreviations hmg coa'
p11
I1
sS'restenosi'
p12
I1
sS'lipid-lowing therapi'
p13
I1
sS'fear'
p14
I1
sS'discharg'
p15
I2
sS'efficacy endpoint'
p16
I2
sS'evidence of ischemia'
p17
I2
sS'cohort studi'
p18
I1
sS'theoretical fear'
p19
I1
sS'placebo-controlled tri'
p20
I1
sS'coronary ev'
p21
I2
sS'non-q wave myocardial infarct'
p22
I1
sS'comparative efficaci'
p23
I1
sS'serious harm'
p24
I1
sS'dl'
p25
I4
sS'randomized placebo-controlled tri'
p26
I1
sS'risk'
p27
I5
sS'index hospit'
p28
I1
sS'arrhythmia'
p29
I1
sS'quantif'
p30
I1
sS'util'
p31
I1
sS'heart association guidelin'
p32
I1
sS'for the secondary prevent'
p33
I1
sS'treatment strategi'
p34
I1
sS'future secondary prevention studi'
p35
I1
sS'high dens'
p36
I1
sS'atorvastatin evalu'
p37
I2
sS'non-fatal myocardial infarct'
p38
I2
sS'cholesterol'
p39
I9
sS'prevent'
p40
I2
sS'revascular'
p41
I8
sS'natur'
p42
I1
sS'density lipoprotein'
p43
I4
sS'diseas'
p44
I8
sS'primary endpoint ev'
p45
I1
sS'concern'
p46
I1
sS'lipid-lowering therapi'
p47
I6
sS'randomized tri'
p48
I1
sS'secondary endpoints included strok'
p49
I1
sS'abbrevi'
p50
I1
sS'cardiolog'
p51
I1
sS'lowering therapi'
p52
I1
sS'evidence of'
p53
I1
sS'incremental clinical benefit'
p54
I1
sS'inpatient initiation of lipid-lowing therapi'
p55
I1
sS'secondary prevention studi'
p56
I1
sS'liver transaminase elev'
p57
I1
sS'secondary prevention statin tri'
p58
I1
sS'cardiovascular death'
p59
I1
sS'association guidelin'
p60
I1
sS'initiation of lipid-lowing therapi'
p61
I1
sS'hospital discharg'
p62
I2
sS'secondary prevention statin'
p63
I1
sS'coa'
p64
I1
sS'non-fatal strok'
p65
I1
sS'high-dose statin therapi'
p66
I1
sS'non-q wav'
p67
I1
sS'studi'
p68
I6
sS'baselin'
p69
I2
sS'incremental benefit'
p70
I3
sS'miracl tri'
p71
I1
sS'guidelin'
p72
I1
sS'american heart association guidelin'
p73
I1
sS'q-wave'
p74
I1
sS'confidence interv'
p75
I3
sS'zocor'
p76
I2
sS'secondary endpoint'
p77
I1
sS'electrocardiogram'
p78
I1
sS'cholesterol target'
p79
I1
sS'aggress'
p80
I2
sS'admission ldl'
p81
I1
sS'relative risk'
p82
I2
sS'high density lipoprotein'
p83
I1
sS'myocardial infarct'
p84
I13
sS'prevention tri'
p85
I1
sS'systolic dysfunct'
p86
I1
sS'criteria'
p87
I1
sS'benefit conf'
p88
I1
sS'ischemia'
p89
I4
sS'strategi'
p90
I2
sS'endpoints included strok'
p91
I1
sS'inpatient initi'
p92
I1
sS'rehospitalization for'
p93
I1
sS'lipoprotein'
p94
I4
sS'liver'
p95
I1
sS'efficaci'
p96
I1
sS'generaliz'
p97
I1
sS'mg'
p98
I4
sS'endpoint'
p99
I8
sS'future secondary prevent'
p100
I1
sS'incremental benefit of combination therapi'
p101
I1
sS'q-wave myocardial infarct'
p102
I3
sS'of lipid-lowing therapi'
p103
I1
sS'clinical ev'
p104
I1
sS'hdl'
p105
I4
sS'heart'
p106
I4
sS'non-q wave myocardi'
p107
I1
sS'ptca'
p108
I2
sS'secondary prevention tri'
p109
I1
sS'normal occur'
p110
I1
sS'stroke'
p111
I2
sS'atorvastatin'
p112
I9
sS'coronary revascular'
p113
I7
sS'occur'
p114
I1
sS'contribut'
p115
I1
sS'trial'
p116
I7
sS'for symptomatic myocardial ischemia'
p117
I1
sS'coronari'
p118
I1
sS'evid'
p119
I1
sS'myocardi'
p120
I2
sS'prognost'
p121
I1
sS'primary endpoint'
p122
I1
sS'clinical benefit'
p123
I7
sS'ascertain'
p124
I1
sS'cardiac death'
p125
I3
sS'aforementioned cohort studi'
p126
I1
sS'in-hospital initiation of lipid-lowering therapi'
p127
I1
sS'atorvastatin treat'
p128
I1
sS'ventricular systolic dysfunct'
p129
I1
sS'percutan'
p130
I1
sS'acute coronari'
p131
I1
sS'elev'
p132
I1
sS'exclus'
p133
I1
sS'non-q-wave myocardial infarct'
p134
I2
sS'randomized placebo-controlled clinical tri'
p135
I1
sS'advisory board member for pf'
p136
I1
sS'simvastatin daili'
p137
I2
sS'infection therapi'
p138
I2
sS'primary efficacy endpoint'
p139
I2
sS'ldl'
p140
I5
sS'advisory board member for'
p141
I1
sS'death'
p142
I4
sS'vascular smooth muscle cell prolifer'
p143
I1
sS'non-pharmacologic lipid-lowering intervent'
p144
I1
sS'of simvastatin daili'
p145
I2
sS'rehospitalization for symptomatic myocardi'
p146
I1
sS'coronary syndrom'
p147
I17
sS'dysfunct'
p148
I1
sS'treatment'
p149
I3
sS'densiti'
p150
I3
sS'secondary endpoints includ'
p151
I1
sS'therapi'
p152
I20
sS'theoretical concern'
p153
I1
sS'lipid-lowering intervent'
p154
I1
sS'placebo-controlled clinical tri'
p155
I1
sS'symptomatic myocardial ischemia'
p156
I2
sS'of lipid-lowering therapi'
p157
I1
sS'invasive strategi'
p158
I1
sS'health car'
p159
I1
sS'in-hospital initiation of'
p160
I1
sS'accru'
p161
I1
sS'benefit'
p162
I8
sS'intervent'
p163
I1
sS'confid'
p164
I3
sS'atorvastatin-treated pati'
p165
I1
sS'harm'
p166
I1
sS'of combination therapi'
p167
I1
sS'aggressive treatment strategi'
p168
I1
sS'interv'
p169
I3
sS'liver transaminas'
p170
I1
sS'cabg'
p171
I2
sS'statin tri'
p172
I1
sS'vascular smooth muscle cel'
p173
I1
sS'statin'
p174
I6
sS'aggressive cholesterol'
p175
I2
sS'event'
p176
I8
sS'syndrom'
p177
I17
sS'admission ldl cholesterol'
p178
I1
sS'admiss'
p179
I4
sS'infarct'
p180
I13
sS'confirm'
p181
I1
sS'mg of simvastatin daili'
p182
I2
sS'pravastatin'
p183
I2
sS'endpoint ev'
p184
I1
sS'health'
p185
I1
sS'surgical coronary revascular'
p186
I1
sS'complic'
p187
I2
sS'caucasian'
p188
I1
sS'ecg'
p189
I2
sS'investig'
p190
I1
sS'patient'
p191
I3
sS'primary composite endpoint'
p192
I1
sS'cell prolifer'
p193
I1
sS'prevention studi'
p194
I1
sS'confer'
p195
I1
sS'vascular smooth muscl'
p196
I1
sS'safety endpoint'
p197
I1
sS'wave myocardial infarct'
p198
I1
sS'in-hospital initi'
p199
I1
sS'pfizer'
p200
I1
sS'hdl cholesterol'
p201
I1
sS'rehospit'
p202
I4
sS'cardiovascular ev'
p203
I2
sS'advisory board'
p204
I1
sS'ldl cholesterol'
p205
I3
sS'miracl'
p206
I9
sS'smooth muscle cell prolifer'
p207
I1
sS'heart protect'
p208
I1
sS'incremental benefit conf'
p209
I1
sS'lipid lowering therapi'
p210
I1
sS'serum cholesterol'
p211
I1
sS'total cholesterol'
p212
I1
sS'ventricular arrhythmia'
p213
I1
sS'for pfiz'
p214
I2
sS'atorvastatin-tr'
p215
I1
sS'of ischemia'
p216
I1
sS'board member for pf'
p217
I1
sS'statins for the secondary prevent'
p218
I1
sS'baseline cholesterol'
p219
I1
sS'daili'
p220
I2
sS'statin therapi'
p221
I8
sS'trial safety endpoint'
p222
I1
sS'abbreviations hmg'
p223
I1
sS'clinical trial safety endpoint'
p224
I1
sS'prevention statin tri'
p225
I1
sS'heart protection studi'
p226
I1
sS'aggrastat'
p227
I2
sS'the secondary prevent'
p228
I1
sS'pharmacolog'
p229
I1
sS'exclusion criteria'
p230
I1
sS'target'
p231
I1
sS'statins for th'
p232
I1
sS'observational studi'
p233
I1
sS'baseline lipid'
p234
I2
sS'mg of'
p235
I2
sS'a-2-z studi'
p236
I1
sS'risk pati'
p237
I2
sS'ac'
p238
I2
sS'included strok'
p239
I1
sS'evalu'
p240
I2
sS'rehospitalization for symptomatic myocardial ischemia'
p241
I1
sS'cardiac ev'
p242
I1
sS'initiation of lipid-lowering therapi'
p243
I1
sS'hospit'
p244
I4
sS'hmg coa'
p245
I1
sS'clinical trial safeti'
p246
I1
sS'clinical tri'
p247
I2
sS'infect'
p248
I2
sS'simvastatin'
p249
I2
sS'risk natur'
p250
I1
sS'index'
p251
I1
sS'aggressive treat'
p252
I1
sS'prolifer'
p253
I1
sS'electrocardiographic q-wav'
p254
I1
sS'transaminase elev'
p255
I1
sS'a-2-z'
p256
I2
sS'muscle cell prolifer'
p257
I1
sS'benefit of combination therapi'
p258
I1
sS'rr'
p259
I5
sS'rehospitalization for symptomat'
p260
I1
sS'protection studi'
p261
I1
sS'myocardial ischemia'
p262
I5
sS'rr relative risk'
p263
I1
sS'secondary prevent'
p264
I5
sS'ischemic ev'
p265
I1
sS'incremental benefit of'
p266
I1
stp267
Rp268
tp269
.